Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 116 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Recurrence 17 Burkitt Lymphoma 14 Lymphoma, Large B-Cell, Diffuse 8 Neoplasms 7 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6 Neoplasms, Plasma Cell 6 Lymphoma 6 Leukemia, Biphenotypic, Acute 5 Immunoglobulin Light-chain Amyloidosis 5 Carcinoma, Non-Small-Cell Lung 5 Prostatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Lymphoma, B-Cell 4 Waldenstrom Macroglobulinemia 3 Neoplasm Metastasis 3 Nausea 3 Lung Neoplasms 3 Leukemia 3 Smoldering Multiple Myeloma 2 Rectal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Paraproteinemias 2 Ovarian Neoplasms 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Down Syndrome 2

Interventions

Prednisone 2 Abiraterone Acetate 2 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 apalutamide 1 Standard of Care 1 Radiosurgery 1 Hydrocortisone 1 Docetaxel 1 Dexamethasone 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Dexamethasone × 90 days × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡